



NEWS FOR IMMEDIATE RELEASE

Contact Information:

Adrienne Choma
President & COO
Saladax Biomedical, Inc.
(201) 240-4072
achoma@saladax.com

SALADAX BIOMEDICAL, INC. SIGNS AGREEMENT WITH STOCKHOLM'S KAROLINSKA UNIVERSITY HOSPITAL *Arrangement Will Allow European Oncologists and Hospitals Easy Access to New Tool for 5-FU Dose Management*

Bethlehem, PA, June 30, 2009 -- Saladax Biomedical, Inc. (www.saladax.com), developer of the Personalized Chemotherapy Management (PCM[®]) line of tests to measure blood levels of cancer drugs, has signed an agreement with The Karolinska University Hospital, of Stockholm, Sweden.

Karolinska will provide clinical laboratory testing for the Saladax 5-Fluorouracil (5-FU) Assay based at their specialty clinical laboratory facility. In collaboration with Karolinska, Saladax can now offer 5-FU testing and 5-FU dose management to hospitals and oncologists throughout Europe that want to offer their patients the benefits of 5-FU dose management without setting up their own laboratory testing.

5-FU, used in combination with other drugs, is the mainstay of treatment for colorectal cancer and is also used in combating head & neck and breast cancer. Current dosing of 5-FU based on Body Surface Area (BSA) results in up to a 30-fold variability in patient blood levels. If the drug blood level is too high, it can cause significant side-effects. Conversely, at too low a level it is clinically ineffective.

Results of a recent clinical study published in the May 2008 issue of the *Journal of Clinical Oncology* confirm that carefully monitoring the level of drug in individual colorectal cancer patients can result in dramatically increased efficacy of treatment, prolonged symptom-free survival and a reduction in serious side-effects.

The principal author of the study, Dr. Erick Gamelin at the Paul Papin Cancer Center in Angers France, reported dosing based on BSA resulted in 68% of patients having sub-therapeutic plasma levels; 17% of patients were over-dosed and only 15% were actually in the optimal therapeutic range. Patients whose 5-FU dose was adjusted during the course of treatment to achieve optimal blood concentrations, experienced a statistically significant (P=0.004) doubling of objective response rate, from 17% to 34%, and a trend towards improvement in median overall survival

from 16 months to 22 months (overall survival was not an endpoint in this study). The most serious side effects were significantly reduced despite increase in 5-FU dosing for the 68% of patients that were found to be under dosed with BSA-based dosing.

“Easy access to the 5-FU PCM Assay will provide oncologists with a proven tool to improve treatment outcomes and a better quality of life for their cancer patients. Optimal 5-FU plasma levels are well-established and guidance for dose adjustment to achieve optimal blood levels will be provided by Karolinska,” stated Professor Olof Beck, who heads the Karolinska clinical laboratory.

“We are very gratified to have a highly respected institution like Karolinska provide 5-FU PCM testing services to our European clients. PCM offers the oncology community a concrete step forward in offering personalized medicine to their cancer patients,” said Dr. Salvatore J. Salamone, CEO of Saladax.

Physicians interested in utilizing the 5-FU PCM Assay should contact Saladax Biomedical for further information.

About Saladax Biomedical, Inc.

Saladax Biomedical, Inc. is a personalized diagnostics company with its main R&D and manufacturing facilities based in Bethlehem, PA. Founded in 2004, Saladax is pioneering the development of an innovative line of proprietary Personalized Chemotherapy Management (PCM[®]) assays to test plasma levels of the most commonly used anti-cancer medicines. In the European Union, Saladax is marketing its 5-FU PCM Assay directly and has obtained a CE Mark for product distribution.

For more information about Saladax, visit www.saladax.com or view our video at <http://www.saladax.com/saladaxvideo>.

About Karolinska University Hospital

Karolinska University Hospital, Stockholm, Sweden, is one of the largest hospitals in Europe and is at the cutting edge of medical research. The hospital has 1,600 beds and employs 15,000 persons. Approximately 2,100 researchers are active at the hospital, making the Karolinska University Hospital a force in establishing Stockholm as a leading region in biomedical research in the world.

#